Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29519637 | 1.00 | ERN1 (0.57) | ERN1MEN1KMT2ATDP1LMNA | |
| SCHEMBL3794351 | 0.83 | TDP1 (0.58) | ERN1MEN1KMT2ATDP1LMNA | |
| SCHEMBL3452795 | 0.81 | NFE2L2 (0.44) | ERN1NFE2L2 | |
| SCHEMBL30828536 | 0.81 | ERN1 (0.42) | ERN1MEN1KMT2ATDP1LMNA | |
| SCHEMBL7009789 | 0.79 | ALDH1A1 (0.53) | ERN1MEN1KMT2ATDP1LMNA | |
| SCHEMBL6495322 | 0.79 | TDP1 (0.46) | ERN1MEN1KMT2ATDP1LMNA | |
| SCHEMBL5412890 | 0.77 | NFE2L2 (0.41) | ERN1NFE2L2 | |
| SCHEMBL16960014 | 0.77 | ERN1 (0.42) | ERN1NFE2L2 | |
| SCHEMBL9245050 | 0.77 | ALDH1A1 (0.48) | ERN1NFE2L2ALDH1A1 | |
| SCHEMBL30011286 | 0.76 | ALDH1A1 (0.54) | ERN1MEN1KMT2ATDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118496215-A | Polyhydroxylated onium derivative with disubstituted benzene ring, preparation method and medical application thereof | 中国药科大学 | 2024-08-16 | — | — | CN | claimed |
| CN-117624148-A | Polyhydroxy sulfonium salt derivative with disubstituted benzene ring, preparation method and medical application thereof | 中国药科大学 | 2024-03-01 | — | — | CN | claimed |
| CN-109312618-A | For hydraulic fracturing and for the method and composition of tracer water flooding | 光谱追踪服务有限责任公司 | 2019-02-05 | — | — | CN | claimed |
| CN-107286549-A | Antibacterial resin and preparation method thereof | 立得光电科技股份有限公司 | 2017-10-24 | — | — | CN | claimed |
| CN-106892803-A | The preparation method of the fluorobenzaldehyde of 2,6 dichloro 3 and the preparation method of fluorine quinolone compounds | 浙江朗华制药有限公司 | 2017-06-27 | — | — | CN | claimed |
| CN-102532640-B | Method of nucleating polyolefin composition with acetal-based compound | MILLIKEN & CO | 2014-11-26 | — | — | CN | claimed |
| CN-103429594-A | Process for preparation of acetals | RELIANCE IND LTD | 2013-12-04 | — | — | CN | claimed |
| CN-103415523-A | Process for preparing alditol acetals | RELIANCE IND LTD | 2013-11-27 | — | — | CN | claimed |
| JP-60038336-A | — | — | None | — | — | JP | disclosed |
| EP-4747234-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747235-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12454502-B2 | Synthesis of deuterated aldehydes | ARIZONA BOARD OF REGENTS ON BEHALF OF ATHE UNIVERSITY OF ARIZONA (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4626554-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| WO-1992004025-A1 | AMINO ACID ANALOGS AS CCK ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
| US-4647565-A | 2-(2-quinazolinylaminoalkoxymethyl)-1,4-dihydropyridine derivatives as cardiovascular agents | PFIZER INC. (US) | 1987-03-03 | — | — | US | disclosed |
| US-4578395-A | Certain aralkylaminoalkyl esters of 1,4 dihydropyridines as antihypertensive | TEIJIN LIMITED (JP) | 1986-03-25 | — | — | US | disclosed |
| EP-0168151-A1 | Dihydropyridine cardiovascular agents | Pfizer Limited (GB) | 1986-01-15 | — | — | EP | disclosed |
| JP-S6038336-A | BENZALDEHYDE DERIVATIVE AND ITS PREPARATION | TEIJIN LTD | 1985-02-27 | — | — | JP | disclosed |
| EP-0128010-A2 | 1,4-Dihydropyridine derivative, process for production thereof and pharmaceutical use thereof | TEIJIN LIMITED (JP) | 1984-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | ERN1 607/4885MEN1 4346/4885KMT2A 4265/4885 |
| US-12454502-B2 | Synthesis of deuterated aldehydes | ADH1C, ADH1A, CBR1 | ERN1 810/4885MEN1 2298/4885KMT2A 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.